|
|
 |
|
 |
September 22, 2005
MDX's Technology Receives Grant From Canadian Institutes of Health Research
Vancouver, BC - (September 22, 2005) MDX Medical Inc. (TSX.V: MDX) announced today that the Canadian Institutes of Health Research (CIHR) has awarded a grant to support research to advance development of the Company's NIRS Urodynamics medical device. The device is a breakthrough in bladder care providing non-invasive monitoring in the diagnosis of urinary incontinence and bladder dysfunction.
Barry Allen, President and Chief Executive Officer, said, "This grant will allow us to devote additional technical resources to accelerate our NIRS Urodynamics device toward commercialization. Additionally, the grant creates a working relationship with the CIHR and will allow MDX to explore collaboration with other government research funding organizations."
Research work covered by the grant will occur over the next year and will be conducted at the UBC Bladder Care Centre. This research will establish baseline factors of NIRS for the bladder as well as establishing characteristic NIRS tracings for each of the major bladder conditions. These tracing patterns will enable the diagnostic capabilities of urodynamics spectrograms, in a similar way that EKG reference patterns characterize cardiomyopathies.
About MDX Medical
MDX Medical Inc.'s focus is on the commercialization of novel, innovative and leading edge medical device technologies for improved diagnosis and treatment of prominent health disorders. The Company�s business strategy is to acquire and commercialize high potential technologies that have reached the "proof of feasibility" or later stages of product development. For more information about MDX, please visit our website at: www.mdxmedical.com.
On behalf of the Board,
"Barry Allen"
President & CEO
MDX Medical Inc.
Certain information contained in this press release may be forward looking and is subject to unknown risks, which could cause actual results to differ materially from those, set forth or implied herein. Although the Company believes that the expectations reflected in such forward looking statements are reasonable, it can give no assurance that such expectations will prove correct.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Larry Horsburgh
Phone: (604) 694-7770, Ext. 112
Email: lhorsburgh@mdxmedical.com |
|  |
|
